Understanding the Impact of HCV and Therapeutic Considerations for the Front-Line Provider
Immunology, Infectious Disease
2.00 AMA PRA Category 1 Credits
- Identify and screen patients at risk for HCV infection, determine which patients should be considered for HCV therapy, and counsel patients accordingly
- Illustrate knowledge gained on new triple-combination therapy combinations that include DAAs and collaborate with HCV specialist in the treatment of patients with chronic hepatitis C.
- Monitor HCV patients on DAA therapy for potential adverse events, drug interactions, and issues relating to drug adherence
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with pmiCME's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of pmiCME.
||AMA PRA Category 1 Credits
||pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
||pmiCME designates this enduring material activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty and Editorial Board
Paul Kwo, MD, (Read Bio), Professor of Medicine, Medical Director, Liver Transplantation, Gastroenterology/Hepatology, Division, Indiana University School of Medicine, Indianapolis, IN
Stephen A. Harrison, MD, LTC(P), MC, (Read Bio), Clinical Associate Professor of Medicine, University of Texas Health Science Center, San Antonio, TX
Carolyn Skowronski, PharmD, Senior Medical Director, pmiCME
Financial Disclosure Statement(s)
Paul Kwo, MD, reports receiving research support from Vertex, Merck, Bristol-Myers Squibb, Gilead, and Abbott. He is on the advisory board for Vertex, Bristol-Myers Squibb, Gilead, Novartis, J&J, Boehringer-Ingelheim, Inhibitex and Merck. He is also a consultant for Bristol-Myers Squibb, Merck, Gilead, Vertex and Roche.
Stephen A. Harrison, MD, reports being on the advisory board for Merck and Vertex. He has been on speaker’s bureaus for Merck and Bristol-Myers Squibb.
Bill Doutre, PharmD, Consensus Medical Communications, has no conflicts of interest to report.
Dr Skowronski holds stock in Merck.
Consensus Medical Communications
Vertex Pharmaceutical Incorporated and Genentech
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached post-activity assessment and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, or DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.